Novo Nordisk A/S (NYSE: NVO) Stock Competitors & Peer Comparison

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, LLY has a market cap of 1.3T. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while LLY trades at $1,354.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas LLY's P/E ratio is 43.57. In terms of profitability, NVO's ROE is +0.54%, compared to LLY's ROE of +0.84%. Regarding short-term risk, NVO is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for NVO.Check LLY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, JNJ has a market cap of 664.8B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while JNJ trades at $276.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas JNJ's P/E ratio is 25.74. In terms of profitability, NVO's ROE is +0.54%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, NVO is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, ABBV has a market cap of 514.9B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while ABBV trades at $291.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas ABBV's P/E ratio is 28.59. In terms of profitability, NVO's ROE is +0.54%, compared to ABBV's ROE of -2.03%. Regarding short-term risk, NVO is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, MRK has a market cap of 362B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while MRK trades at $146.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas MRK's P/E ratio is 45.70. In terms of profitability, NVO's ROE is +0.54%, compared to MRK's ROE of +0.05%. Regarding short-term risk, NVO is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for NVO.Check MRK's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, NVS has a market cap of 307B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while NVS trades at $162.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas NVS's P/E ratio is 18.71. In terms of profitability, NVO's ROE is +0.54%, compared to NVS's ROE of +0.25%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, AZN has a market cap of 289.1B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while AZN trades at $186.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas AZN's P/E ratio is 20.13. In terms of profitability, NVO's ROE is +0.54%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVO is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for NVO.Check AZN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, AMGN has a market cap of 248.8B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while AMGN trades at $460.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas AMGN's P/E ratio is 20.57. In terms of profitability, NVO's ROE is +0.54%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, NVO is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, GILD has a market cap of 206.9B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while GILD trades at $166.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas GILD's P/E ratio is -427.74. In terms of profitability, NVO's ROE is +0.54%, compared to GILD's ROE of -0.22%. Regarding short-term risk, NVO is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for NVO.Check GILD's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, PFE has a market cap of 167.5B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while PFE trades at $29.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas PFE's P/E ratio is 9.63. In terms of profitability, NVO's ROE is +0.54%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVO is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for NVO.Check PFE's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, BMY has a market cap of 127.1B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while BMY trades at $62.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas BMY's P/E ratio is 10.48. In terms of profitability, NVO's ROE is +0.54%, compared to BMY's ROE of +0.44%. Regarding short-term risk, NVO is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BMY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, SNY has a market cap of 113.7B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while SNY trades at $47.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas SNY's P/E ratio is 10.24. In terms of profitability, NVO's ROE is +0.54%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVO is less volatile compared to SNY. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SNY's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, GSK has a market cap of 101.8B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while GSK trades at $50.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas GSK's P/E ratio is 10.87. In terms of profitability, NVO's ROE is +0.54%, compared to GSK's ROE of +0.23%. Regarding short-term risk, NVO is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for NVO.Check GSK's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, CELG-RI has a market cap of 94.8B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while CELG-RI trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.54%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, NVO is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CELG-RI's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, BIIB has a market cap of 36.7B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while BIIB trades at $248.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas BIIB's P/E ratio is 15.69. In terms of profitability, NVO's ROE is +0.54%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, NVO is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.54%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, GRFS has a market cap of 7.1B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while GRFS trades at $8.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas GRFS's P/E ratio is 9.69. In terms of profitability, NVO's ROE is +0.54%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, NVO is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while OGN trades at $13.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas OGN's P/E ratio is 4.13. In terms of profitability, NVO's ROE is +0.54%, compared to OGN's ROE of +0.22%. Regarding short-term risk, NVO is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check OGN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, AMRN has a market cap of 241.1M. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while AMRN trades at $11.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas AMRN's P/E ratio is -116.55. In terms of profitability, NVO's ROE is +0.54%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, NVO is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for NVO.Check AMRN's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, MIRA has a market cap of 23.3M. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while MIRA trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas MIRA's P/E ratio is -0.38. In terms of profitability, NVO's ROE is +0.54%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, SCLX has a market cap of 11.7M. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while SCLX trades at $1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas SCLX's P/E ratio is -0.04. In terms of profitability, NVO's ROE is +0.54%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, SCLXW has a market cap of 7.6M. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while SCLXW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.54%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVO is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVO's ROE is +0.54%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVO is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BDSIW's competition here

Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 177.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $40.31 on the NYSE, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 10.03, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.54%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here